Patients with serious and/or life-threatening conditions can receive compassionate use access to promising treatments when they are not able to participate in a clinical trial and have no comparable or effective therapeutic options. The number of patients receiving access through these mechanisms remains very low.  Biopharmaceutical companies can benefit from these programs, where evidence has been successfully used to support…